Inari Medical (NARI)
(Delayed Data from NSDQ)
$44.23 USD
+0.76 (1.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $44.25 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.23 USD
+0.76 (1.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $44.25 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Zacks News
Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down
by Zacks Equity Research
Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 9.43% and 1.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand
by Zacks Equity Research
Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.
Why Is Steris (STE) Down 3.4% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari Medical, Inc. (NARI) Up 17.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inari Medical's (NARI) PEERLESS II RCT to Boost Patient Outcome
by Zacks Equity Research
Inari Medical's (NARI) latest announcement of first patient enrollment in PEERLESS II RCT is likely to aid in changing guidelines in treating intermediate-risk PE patients globally.
Reasons to Retain Inari Medical (NARI) in Your Portfolio Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is a concern.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance.
Alcon (ALC) Unveils New Progress in Presbyopia Correcting IOLs
by Zacks Equity Research
Alcon's (ALC) Clareon Vivity IOL highlights proven results and high levels of patient satisfaction. It will offer a similar halo profile compared with a monofocal IOL.
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
by Zacks Equity Research
Charles River's (CRL) RMS organic revenue growth is primarily driven by research model services, particularly the Insourcing Solutions business.
Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Globus Medical's (GMED) legacy business continues to drive share growth across its U.S. spine and trauma portfolios in the third quarter.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), led by its strong global presence.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.
Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q3
by Zacks Equity Research
Myriad Genetics' (MYGN) third-quarter 2023 revenues increase year over year, driven by strong testing volume improvement across all its businesses.
Insulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View Up
by Zacks Equity Research
Insulet's (PODD) third-quarter 2023 revenues increase year over year as a result of continued high demand for Omnipod 5.
Inari Medical, Inc. (NARI) Loses -27.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Inari Medical, Inc. (NARI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.
Teleflex (TFX) Q3 Earnings Top Estimates, 2023 Outlook Up
by Zacks Equity Research
Teleflex's (TFX) year-over-year revenue growth was driven by all global product categories in Q3.
Haemonetics (HAE) Q2 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
The robust volume growth and price benefits in the Plasma business driven by strong momentum in U.S. collections and price benefit Haemonetics' (HAE) fiscal second-quarter results.
Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.
Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.
Envista (NVST) Q3 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Envista's (NVST) Q3 performance is impacted by the negative impact of Russia and the weakness of higher-end specialty procedures in developed markets.
CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.